EP0972202A1 - Process for diagnosing transmissible spongiform encephalopathy - Google Patents
Process for diagnosing transmissible spongiform encephalopathyInfo
- Publication number
- EP0972202A1 EP0972202A1 EP98913583A EP98913583A EP0972202A1 EP 0972202 A1 EP0972202 A1 EP 0972202A1 EP 98913583 A EP98913583 A EP 98913583A EP 98913583 A EP98913583 A EP 98913583A EP 0972202 A1 EP0972202 A1 EP 0972202A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- blood serum
- protein
- concentration
- disease
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Definitions
- the invention relates to a method for recognizing a disease of an organism from a transmissible spongiform encephalopathy, the concentration of the ⁇ -subunit of the protein S100 in a body fluid of the organism being determined in vitro and the exceeding of a limit concentration of the ⁇ -subunit of the S100 protein is taken as an indication of the presence of the disease.
- the transmissible spongiform encephalopathies include Creutzfeldt-Jakob disease (CJD) in humans, scraping in sheep and goats and bovine spongiform encephalopathy (BSE) in cattle.
- CJD Creutzfeldt-Jakob disease
- BSE bovine spongiform encephalopathy
- NVCD new form of Creutzfeldt-Jakob disease
- Creutzfeldt-Jakob disease or BSE disease Treatment of Creutzfeldt-Jakob disease or BSE disease is currently not possible. However, it is possible to treat the symptoms of Creutzfeldt-Jakob disease and to delay the progression of the disease. Early detection of the disease is therefore desirable. It is also important to safely rule out other causes of dementia. The early detection of any disease of transmissible spongiform encephalopathy is of particular importance, but also when researching the possible transmission routes.
- a quantitative immuno-luminescence serum test for the protein S100 is marketed by AB Sangtec Medical, Bromma, Sweden, under the trade name LIA-mat Sangtec 100.
- the serum test is suitable for use in cerebrospinal fluid as well as in blood serum.
- the protein S100 is an acidic calcium-binding protein with a molecular weight of 21,000, which occurs naturally as homodimer and heterodimer of two subunits ⁇ S100 and ßSlOO.
- the ß subunit (SS100) occurs specifically only in glial cells and Schwann cells of the brain.
- the well-known serum test only reacts to the ß subunits (ßSlOO).
- Protein S100 is known to have a biological half-life of two hours due to its degradation by the kidneys. In the case of temporary brain damage, the concentration of the ⁇ -subunit of the protein S100 in the cerebrospinal fluid and the blood serum therefore drops sharply within a short time.
- the invention has for its object to develop a method of the type described above so that it can be carried out with less effort.
- the extraction of cerebrospinal fluid is fundamentally complex. In cattle, it is associated with considerable difficulties.
- this object is achieved in a method of the type described in the introduction in that the body fluid is a blood serum of the organism.
- the concentration of the ⁇ -subunit of the protein S100 in the blood serum is determined, conspicuous concentrations can be detected if there is a disease of transmissible spongiform encephalopathy.
- the increased concentrations of the ⁇ -subunit of the protein S100 in the blood serum are not observed in every case of a disease of transmissible spongiform encephalopathy, and they are also not restricted to such a disease.
- the determination of the concentration of the ⁇ -subunit of the protein S100 in the blood serum is simply a very effective addition to the previous differential diagnosis of transmissible spongiform encephalopathies.
- the limit concentration that speaks in the new method for the presence of a disease in transmissible spongiform encephalopathy is between 150 and 300 pg / ml blood serum. As the limit concentration increases, the specificity of the criterion is naturally increased, but its sensitivity is reduced.
- the range of 150 to 300 pg / ml blood serum takes into account the fact that in different organisms, i.e. H. For example, different animal species that fluctuate within certain limits due to the general composition of the blood serum, which indicates the presence of a transmissible spongiform encephalopathy limit concentration of the ⁇ -subunit of the protein S100.
- a reasonable limit concentration is between 180 and 260 pg / ml blood serum and preferably 220 pg / ml blood serum, i.e. H. between 200 and 240 pg / ml blood serum.
- the limit concentration of 220 pg / ml blood serum has shown a sensitivity of about 76% of all definitive and probable cases of Creutzfeldt-Jakob diseases and a specificity of over 82% when testing the new method.
- the positive predictive value was 86% and the negative predictive value was 70%.
- a reasonable limit concentration is 500 pg / ml blood serum, i.e. H. between 400 and 600 pg / ml blood serum.
- the sensitivity and, above all, the specificity of the new method can be significantly increased if the concentration of the ⁇ -subunit of the protein S100 in blood sera taken from the organism at different times determines, whereby only a continuous exceeding of the limit concentration indicates the existence of the disease is evaluated.
- a quick one A drop in the concentration of the SlOO protein indicates a temporary, harmful effect on the brain.
- transmissible spongiform encephalopathy however, the damage to the brain progresses with the known fatal consequences. This is in line with persistent high concentrations of the ⁇ -subunit of the protein SlOO in blood sera taken from the organism at different times. Due to a larger number of blood sera from the same organism, it is also easier to recognize and separate out low individual values, which has a positive effect on the sensitivity of the new method.
- the concentration of the ⁇ -subunit of the protein SlOO in the blood serum must be determined with a detection limit and a resolution of better than 100 pg / ml blood serum.
- a detection limit and a resolution of better than 50 pg / ml blood serum, preferably at least 20 pg / ml blood serum should be used.
- the known quantitative immune-luminescence serum test for the protein SlOO with antibodies to the ⁇ -subunit of the protein SlOO can be used.
- the ⁇ -subunits of the SlOO protein are fixed in a first incubation step on antibodies which are themselves fixed and in a second incubation step are labeled with antibodies which are in turn labeled, the antibodies being monoclonal antibodies SMST 12, SMSK 25 and SMSK 28.
- the blood serum of 224 patients who were suspected of Creutzfeldt-Jakob disease was examined. In 65 cases the diagnosis of Creutzfeldt-Jakob disease was confirmed neuropathologically, 43 cases were probable diseases, 36 cases were possible diseases, 6 cases were genetic diseases and 74 patients had other diseases associated with dementia. In addition to these 224 cases, the blood serum of 35 patients with non-dementia diseases was examined, which can be regarded as a control sample.
- a classification as probable Creutzfeldt-Jakob disease was made if there was progressive dementia of less than two years and if there were typical EEG changes [periodic Sharp-Wave complexes (PSWC)] and if at least two of the following four clinical ones Criteria were met:
- a possible Creutzfeldt-Jakob disease was assumed if there was progressive dementia of less than two years and if of the four clinical ones mentioned above Symptoms 1 to 4 were given at least two, but there was no atypical EEG or no EEG at all. All other cases were classified as other diseases.
- Blood serum samples were taken from the patients and cooled to -80 ° C within 24 hours. The concentration of the ⁇ -subunit of the protein SlOO in the blood sera was carried out using a quantitative immuno-luminescence serum test (LIA-mat Sangtec 100 from AB Sangtec Medical, Bromma, Sweden). This serum test is commercially available. It is a two-sided antibody test (sandwich principle) with monoclonal antibodies.
- the ⁇ -subunits of the SlOO protein are bound to a substrate and in the second step marked with a tracer, which is a luminescence tracer.
- the serum test is evaluated using a LIA mat luminescence analyzer from Byk Sangtec using the standards supplied with the LIA-mat Sangtec 100 serum test. The serum test was carried out exactly according to the instructions for use attached to it, to which express reference is made here.
- the attached boxplot diagram shows the concentrations of the ⁇ -subunit of the protein SlOO in the blood serum for the definitive and probable CJD cases, the possible CJD cases, the other dementia and the non-dementia cases.
- the 10th, 25th, 50th, 75th and 90th percentiles are given in the box plots of the ßSOO concentrations, as well as the individual values which lie outside these ranges, in particular the concentrations of the ß-subunit of the protein S100 were in the definitive and probable CJD cases, graphically summarized, between 95 pg / ml blood serum and 2016 pg / ml blood serum.
- the mean was 493 pg / ml blood serum and the standard deviation was 386 pg / ml blood serum.
- the concentrations were between 120 pg / ml blood serum and 2016 pg / ml blood serum with an average of 552 pg / ml blood serum and a standard deviation of 440 pg / ml blood serum.
- the ßSlOO concentrations were between 95 pg / ml blood serum and 1199 pg / ml blood serum with an average value of 405 pg / ml blood serum and a standard deviation of 269 pg / ml blood serum.
- the ßSlOO concentration was between 0 pg / ml blood serum and 742 pg / ml blood serum, the mean value being 194 pg / ml blood serum and the standard deviation being 178 pg / ml blood serum.
- the genetic cases are not listed in the boxplot diagram. These were two cases of fatal familial insomnia (FFI), in which ßSlOO concentrations of 0 pg / ml blood serum and 22 pg / ml blood serum were found.
- FFI fatal familial insomnia
- a patient with an insert mutation had a concentration of the ⁇ -subunit of the protein SlOO of 178 pg / ml blood serum.
- a patient with Gerstmann-St syndrome (GSS) and two patients with a V 2001 mutation had ßSlOO concentrations of 1434 pg / ml, 296 pg / ml and 757 pg / ml blood serum.
- the attached Kaplan-Meier curves show the survival rates of CJD sufferers who were classified into three different groups according to the initially detectable concentration of the ⁇ -subunit of the protein SlOO in blood serum.
- the course of the Kaplan-Meier curves shows an interaction between the concentration of ßSlOO and the medium-term mortality.
- the medium-term mortality is higher the higher the initial concentration of ßSlOO.
- a higher concentration of ßSlOO tends to indicate that the disease has already progressed; or vice versa, the concentration of ßSlOO increases with the progress of the CJD disease.
- Table III documents the applicability of the quantitative examination of the blood serum to the ⁇ -subunit of the protein SlOO to detect scrapie disease (a transmissible spongiform encephalopathy) in hamsters.
- the sample included five blood sera from five diseased animals, partially intracerebral and partially abdominally infected, and five blood sera from healthy animals as a control.
- a limit of 500 pg / ml results in a sensitivity of 80% and a specificity of 100%. There is no difference between the intracerebral and the abdominally infected animals.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19707230 | 1997-02-24 | ||
DE1997107230 DE19707230C2 (en) | 1997-02-24 | 1997-02-24 | Method for recognizing a disease of an organism from transmissible spongiform encephalopathy |
PCT/EP1998/001041 WO1998037420A1 (en) | 1997-02-24 | 1998-02-24 | Process for diagnosing transmissible spongiform encephalopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0972202A1 true EP0972202A1 (en) | 2000-01-19 |
Family
ID=7821245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98913583A Withdrawn EP0972202A1 (en) | 1997-02-24 | 1998-02-24 | Process for diagnosing transmissible spongiform encephalopathy |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0972202A1 (en) |
DE (1) | DE19707230C2 (en) |
WO (1) | WO1998037420A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE447713T1 (en) * | 1998-11-05 | 2009-11-15 | Univ Michigan | S100 PROTEINS AND AUTOANTIBODIES AS SERUM MARKERS FOR CANCER |
AU2001265714A1 (en) * | 2000-06-14 | 2001-12-24 | Universite Libre De Bruxelles | Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4654313A (en) * | 1983-11-25 | 1987-03-31 | The Washington University | Methods for the determination of brain antigens |
US4892814A (en) * | 1987-06-22 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Method for distinguishing Creutzfeldt-Jakob disease from other dementias |
-
1997
- 1997-02-24 DE DE1997107230 patent/DE19707230C2/en not_active Expired - Fee Related
-
1998
- 1998-02-24 EP EP98913583A patent/EP0972202A1/en not_active Withdrawn
- 1998-02-24 WO PCT/EP1998/001041 patent/WO1998037420A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9837420A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998037420A1 (en) | 1998-08-27 |
DE19707230C2 (en) | 2000-01-13 |
DE19707230A1 (en) | 1998-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60200615T2 (en) | PROCESS AND MEANS FOR THE DIFFERENTIAL DIAGNOSIS OF THE DESIGN OF THE ALZHEIMER TYPE | |
EP0276723B1 (en) | Precursor protein of APC polypeptide, DNA coding therefor and diagnostic use of the DNA and protein | |
EP2556375A1 (en) | New formulations for diagnosis of alzheimer's disease | |
DE69933707T2 (en) | SERUM AMYLOID A AS A MARKER FOR INFLAMMATORY RESPONSE, MILK QUALITY AND THE PRESENCE OF KOLOSTRUM IN MILK | |
DE19918141A1 (en) | Diagnosing transmissible spongiform encephalopathy, particularly before appearance of clinical symptoms, by detecting specific markers in blood cells | |
DE69704279T2 (en) | METHOD FOR DETECTING AND / OR QUANTITATIVELY DETERMINING A GLIOTOXIC FACTOR | |
DE10152677A1 (en) | Antibodies for the specific detection of pathogenic prions of human origin and the detection methods performed with them | |
DE69733957T2 (en) | PROCEDURE FOR DETECTING THE PRESENCE OF BRAIN SPECIFIC PROTEIN S-100 BETA | |
EP0972202A1 (en) | Process for diagnosing transmissible spongiform encephalopathy | |
Weizman et al. | Reduced 3H-imipramine binding but unaltered 3H-serotonin uptake in platelets of adolescent enuretics | |
WO2005050219A1 (en) | Quick test for the diagnosis of alzheimer' disease | |
EP0267356B1 (en) | Process and test device for the detection of cell lesions | |
DE10328830A1 (en) | Detection of protease-resistant prion protein after asymmetric interaction | |
WO2009118151A1 (en) | Method for diagnosing and treating chronic psychiatric illnesses and markers and targets for such methods | |
DE69725460T2 (en) | DIAGNOSIS OF SPONGIFORM DISEASE | |
Robinson-Agramonte et al. | Differential regulation of IgG-NMO autoantibodies on S100Beta protein and disability in relapsing neuromyelitis optica | |
EP3149485B1 (en) | Method for diagnosing a disease or a risk to develop a disease transmitted via the alternative pathway of the complement system | |
EP1099116B1 (en) | Method and kit for the detection of central nervous system tissue in heated meat products | |
WO2008138475A1 (en) | Use of crmp1 as a marker for chronic psychiatric illnesses and monoclonal antibodies against crmp1 | |
DE102004024674A1 (en) | Means and methods for the diagnosis, prophylaxis and therapy of connective tissue diseases | |
DE69128642T2 (en) | IMMUNADSORBENS FOR DIAGNOSIS OF EPILEPSY AND THE RISK GROUP | |
EP1241478B1 (en) | Method for detecting the pathogenesis and/or diagnosing transmissible spongiform encephalopathies | |
EP0565903B1 (en) | Method for the immunological determination of one or more analytes | |
DE102022128645A1 (en) | APPLICATION OF SAA COMBINED WITH CTNI | |
AT500613B1 (en) | Diagnosing Down's syndrome, Alzheimer's disease or Pick's disease comprises determining disintegrin and metalloprotease with thrombospondin motif in a blood or serum sample and comparing with a standard |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990924 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 20020213 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030902 |